CO2017010845A2 - Método para aumentar el porcentaje de las especies multiméricas de fragmento de unión a antígeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomérico - Google Patents
Método para aumentar el porcentaje de las especies multiméricas de fragmento de unión a antígeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monoméricoInfo
- Publication number
- CO2017010845A2 CO2017010845A2 CONC2017/0010845A CO2017010845A CO2017010845A2 CO 2017010845 A2 CO2017010845 A2 CO 2017010845A2 CO 2017010845 A CO2017010845 A CO 2017010845A CO 2017010845 A2 CO2017010845 A2 CO 2017010845A2
- Authority
- CO
- Colombia
- Prior art keywords
- fragment
- antigen
- percentage
- increase
- dsfv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
RESUMEN La presente invención proporciona un método para aumentar el porcentaje del monómero en una composición de moléculas del anticuerpo expresadas de manera recombinante, caracterizado porque la molécula del anticuerpo comprende al menos un Fv con especificidad hacia un antígeno de interés que comprende un VH y un VL, en donde el VH y el VL están conectados directa o indirectamente por medio de uno o más enlazadores y son estabilizados por medio de un enlace de disulfuro entre los mismos, el método comprende: a) una etapa de conversión térmica manteniendo la composición que comprende la molécula del anticuerpo a una temperatura en el intervalo de 30 a 60 °C durante un periodo de al menos 1 hora, en donde la etapa a) es efectuada en la presencia de un agente reductor o después del tratamiento con un agente reductor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506869.5A GB201506869D0 (en) | 2015-04-22 | 2015-04-22 | Method |
| PCT/EP2016/059050 WO2016170137A1 (en) | 2015-04-22 | 2016-04-22 | Method for increasing the percentage of monomeric antibody fab-dsfv multimeric species |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017010845A2 true CO2017010845A2 (es) | 2018-03-20 |
Family
ID=53299018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0010845A CO2017010845A2 (es) | 2015-04-22 | 2017-10-25 | Método para aumentar el porcentaje de las especies multiméricas de fragmento de unión a antígeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomérico |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10829565B2 (es) |
| EP (1) | EP3286220A1 (es) |
| JP (1) | JP6901402B2 (es) |
| KR (1) | KR20170138551A (es) |
| CN (1) | CN107683290B (es) |
| AU (1) | AU2016251960A1 (es) |
| BR (1) | BR112017022472A2 (es) |
| CA (1) | CA2983537A1 (es) |
| CL (1) | CL2017002677A1 (es) |
| CO (1) | CO2017010845A2 (es) |
| EA (1) | EA201792325A1 (es) |
| GB (1) | GB201506869D0 (es) |
| IL (1) | IL255094A0 (es) |
| MX (1) | MX2017013419A (es) |
| SG (1) | SG11201708430VA (es) |
| WO (1) | WO2016170137A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| EP3551664B1 (en) * | 2016-12-09 | 2021-02-17 | OSE Immunotherapeutics | Antibodies and polypeptides directed against cd127 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| US4877868A (en) | 1986-03-12 | 1989-10-31 | Neorx Corporation | Radionuclide antibody coupling |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
| ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| US7993864B2 (en) | 2002-12-03 | 2011-08-09 | Ucb Pharma S.A. | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| NZ554520A (en) | 2004-10-22 | 2010-03-26 | Amgen Inc | Methods for refolding of recombinant antibodies |
| GB0425534D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
| JP2009509535A (ja) | 2005-09-27 | 2009-03-12 | アムニクス， インコーポレイテッド | タンパク様薬剤およびその使用 |
| CN101583370A (zh) * | 2005-09-27 | 2009-11-18 | 阿穆尼克斯公司 | 蛋白质药物及其用途 |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
| EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
| US20090269343A1 (en) | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
| JP5529869B2 (ja) | 2008-08-14 | 2014-06-25 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法 |
| CA2737580A1 (en) * | 2008-09-26 | 2010-04-01 | Schering Corporation | High titer antibody production |
| EA201100527A1 (ru) * | 2008-09-26 | 2011-10-31 | Юсб Фарма С.А. | Биологические продукты |
| PL2424889T3 (pl) * | 2009-04-30 | 2016-01-29 | Ablynx Nv | Sposób wytwarzania przeciwciał domenowych |
| EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| GB201001791D0 (en) * | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
| TR201903279T4 (tr) | 2010-03-25 | 2019-03-21 | Ucb Biopharma Sprl | Disülfür stabilize edilmiş DVD-IG molekülleri. |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| PT2560993T (pt) * | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| CA2796633C (en) * | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| EP2696895A1 (en) | 2011-04-13 | 2014-02-19 | Biomay Ag | IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES |
| HRP20240230T1 (hr) | 2011-10-11 | 2024-04-26 | F. Hoffmann - La Roche Ag | Poboljšani sklop bispecifičnih protutijela |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| EP2776466B1 (en) | 2011-11-11 | 2017-08-23 | UCB Biopharma SPRL | Albumin binding antibodies and binding fragments thereof |
| EP2822597A1 (en) | 2012-03-09 | 2015-01-14 | UCL Business Plc. | Chemical modification of antibodies |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| EP3050896B1 (en) * | 2013-09-27 | 2021-07-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| EP3337820B1 (en) | 2015-08-17 | 2020-10-14 | Lupin Limited | An improved refolding process for antibody's fragments |
-
2015
- 2015-04-22 GB GBGB1506869.5A patent/GB201506869D0/en not_active Ceased
-
2016
- 2016-04-22 EA EA201792325A patent/EA201792325A1/ru unknown
- 2016-04-22 US US15/568,018 patent/US10829565B2/en active Active
- 2016-04-22 MX MX2017013419A patent/MX2017013419A/es unknown
- 2016-04-22 WO PCT/EP2016/059050 patent/WO2016170137A1/en active Application Filing
- 2016-04-22 SG SG11201708430VA patent/SG11201708430VA/en unknown
- 2016-04-22 CA CA2983537A patent/CA2983537A1/en active Pending
- 2016-04-22 CN CN201680031354.XA patent/CN107683290B/zh active Active
- 2016-04-22 EP EP16721103.6A patent/EP3286220A1/en active Pending
- 2016-04-22 JP JP2017555395A patent/JP6901402B2/ja active Active
- 2016-04-22 BR BR112017022472A patent/BR112017022472A2/pt active Search and Examination
- 2016-04-22 AU AU2016251960A patent/AU2016251960A1/en not_active Abandoned
- 2016-04-22 KR KR1020177033852A patent/KR20170138551A/ko active Search and Examination
-
2017
- 2017-10-17 IL IL255094A patent/IL255094A0/en unknown
- 2017-10-20 CL CL2017002677A patent/CL2017002677A1/es unknown
- 2017-10-25 CO CONC2017/0010845A patent/CO2017010845A2/es unknown
-
2020
- 2020-10-23 US US17/078,130 patent/US11834514B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11834514B2 (en) | 2023-12-05 |
| GB201506869D0 (en) | 2015-06-03 |
| EA201792325A1 (ru) | 2018-04-30 |
| CN107683290B (zh) | 2022-01-04 |
| JP6901402B2 (ja) | 2021-07-14 |
| AU2016251960A1 (en) | 2017-11-02 |
| JP2018515453A (ja) | 2018-06-14 |
| BR112017022472A2 (pt) | 2018-07-17 |
| IL255094A0 (en) | 2017-12-31 |
| US20180142039A1 (en) | 2018-05-24 |
| MX2017013419A (es) | 2018-02-09 |
| CA2983537A1 (en) | 2016-10-27 |
| US20210079120A1 (en) | 2021-03-18 |
| CL2017002677A1 (es) | 2018-03-23 |
| KR20170138551A (ko) | 2017-12-15 |
| WO2016170137A1 (en) | 2016-10-27 |
| EP3286220A1 (en) | 2018-02-28 |
| CN107683290A (zh) | 2018-02-09 |
| SG11201708430VA (en) | 2017-11-29 |
| US10829565B2 (en) | 2020-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017010845A2 (es) | Método para aumentar el porcentaje de las especies multiméricas de fragmento de unión a antígeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomérico | |
| AR096617A1 (es) | Anticuerpos anti-tweakr y sus usos | |
| CY1124252T1 (el) | Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου | |
| AR113342A1 (es) | Anticuerpos específicos cd47 / pd-l1 | |
| CL2019001926A1 (es) | Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017). | |
| UY36194A (es) | Anticuerpos anti-tau humanizados | |
| PE20180499A1 (es) | Anticuerpos de union a tau | |
| AR102239A1 (es) | Anticuerpos anti-ox40 humanizados y sus usos | |
| BR112018007152A2 (pt) | construtos de polipeptídeo de ligação a antígeno compreendendo cadeias leves kappa e lambda e usos dos mesmos | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| PE20171654A1 (es) | Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| CO2017010385A2 (es) | Método de monomerización de moléculas de anticuerpos recombinantes | |
| EA201690325A1 (ru) | БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ | |
| EA201591465A1 (ru) | Специфичные участки для модификации антител для получения иммуноконъюгатов | |
| PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
| AR100680A1 (es) | Anticuerpos anti-dr5 y moléculas que comprenden dominios de unión de dr5 de los mismos | |
| CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
| CO2018004930A2 (es) | Moléculas de unión específicas para asct2 | |
| CO2018000652A2 (es) | Anticuerpo anti-epha4 | |
| EA202190955A1 (ru) | Способы снижения агрегации биспецифических антител | |
| CL2017000912A1 (es) | Anticuerpos que se unen a ccr6 y sus usos | |
| MX2015009547A (es) | Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo. | |
| PE20190633A1 (es) | Anticuerpos anti-gm-csf y usos de los mismos | |
| EA201891594A1 (ru) | Антитела к il-17c |